KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme (CME) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Cme (CME) over the last 17 years, with Q3 2025 value amounting to $2.4 billion.

  • Cme's Cash & Equivalents rose 537.01% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 537.01%. This contributed to the annual value of $2.9 billion for FY2024, which is 67.31% down from last year.
  • Per Cme's latest filing, its Cash & Equivalents stood at $2.4 billion for Q3 2025, which was up 537.01% from $2.0 billion recorded in Q2 2025.
  • In the past 5 years, Cme's Cash & Equivalents ranged from a high of $2.9 billion in Q4 2023 and a low of $936.4 million during Q1 2021
  • Over the past 5 years, Cme's median Cash & Equivalents value was $2.0 billion (recorded in 2025), while the average stood at $2.0 billion.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 11846.43% in 2022, then plummeted by 2348.83% in 2023.
  • Cme's Cash & Equivalents (Quarter) stood at $2.8 billion in 2021, then dropped by 4.05% to $2.7 billion in 2022, then rose by 7.05% to $2.9 billion in 2023, then dropped by 0.67% to $2.9 billion in 2024, then decreased by 15.41% to $2.4 billion in 2025.
  • Its Cash & Equivalents was $2.4 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $1.4 billion in Q1 2025.